BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22249510)

  • 1. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure.
    McCullough PA; Olobatoke A; Vanhecke TE
    Rev Cardiovasc Med; 2011; 12(4):200-10. PubMed ID: 22249510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical experience using galectin-3 in heart failure.
    McCullough PA
    Clin Chem Lab Med; 2014 Oct; 52(10):1425-31. PubMed ID: 24810562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-3: a novel mediator of heart failure development and progression.
    de Boer RA; Voors AA; Muntendam P; van Gilst WH; van Veldhuisen DJ
    Eur J Heart Fail; 2009 Sep; 11(9):811-7. PubMed ID: 19648160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
    Meijers WC; van der Velde AR; de Boer RA
    Expert Rev Mol Diagn; 2014 Apr; 14(3):257-66. PubMed ID: 24606321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
    Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
    Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
    Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
    Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive review of the prognostic value of galectin-3 in heart failure.
    Coburn E; Frishman W
    Cardiol Rev; 2014; 22(4):171-5. PubMed ID: 24407048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of galectin-3 in case management across the spectrum of heart failure.
    McCullough P; de Boer RA; Edelmann F; Lewis CM; Maisel AS
    Rev Cardiovasc Med; 2014; 15(3):197-207. PubMed ID: 25290725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction.
    Gruson D; Mancini M; Ahn SA; Rousseau MF
    Clin Chim Acta; 2014 Feb; 429():189-93. PubMed ID: 24365381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.
    Nishii M; Inomata T; Takehana H; Naruke T; Yanagisawa T; Moriguchi M; Takeda S; Izumi T
    J Am Coll Cardiol; 2008 Jun; 51(24):2329-35. PubMed ID: 18549918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events.
    Tziakas DN; Chalikias GK; Stakos D; Chatzikyriakou SV; Papazoglou D; Mitrousi K; Lantzouraki A; Thomaidi A; Boudoulas H; Konstantinides S
    Eur J Prev Cardiol; 2012 Feb; 19(1):62-71. PubMed ID: 20479644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurohormonal and inflammatory markers as predictors of short-term outcome in patients with heart failure and cardiac resynchronization therapy.
    Glick A; Michowitz Y; Keren G; George J
    Isr Med Assoc J; 2006 Jun; 8(6):391-5. PubMed ID: 16833167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
    Leone M; Iacoviello M
    Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
    Sharma UC; Pokharel S; van Brakel TJ; van Berlo JH; Cleutjens JP; Schroen B; André S; Crijns HJ; Gabius HJ; Maessen J; Pinto YM
    Circulation; 2004 Nov; 110(19):3121-8. PubMed ID: 15520318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center.
    Amir O; Paz H; Ammar R; Yaniv N; Schliamser JE; Lewis BS
    Isr Med Assoc J; 2008 Feb; 10(2):109-12. PubMed ID: 18432021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.
    Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L
    Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-3 in heart failure: high levels are associated with all-cause mortality.
    Ueland T; Aukrust P; Broch K; Aakhus S; Skårdal R; Muntendam P; Gullestad L
    Int J Cardiol; 2011 Aug; 150(3):361-4. PubMed ID: 21641051
    [No Abstract]   [Full Text] [Related]  

  • 20. Health status identifies heart failure outpatients at risk for hospitalization or death.
    Heidenreich PA; Spertus JA; Jones PG; Weintraub WS; Rumsfeld JS; Rathore SS; Peterson ED; Masoudi FA; Krumholz HM; Havranek EP; Conard MW; Williams RE;
    J Am Coll Cardiol; 2006 Feb; 47(4):752-6. PubMed ID: 16487840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.